



Clinical trial results:

A phase I, open-label study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' seasonal trivalent influenza vaccine adjuvanted with various doses of the AS03 (GSK2186877A), administered in healthy children aged 6 to 35 months.

Summary

EudraCT number	2010-018392-22
Trial protocol	ES
Global end of trial date	13 December 2010

Results information

Result version number	v3 (current)
This version publication date	23 July 2022
First version publication date	01 February 2015
Version creation reason	• Correction of full data set Correction of full data set and alignment between registries.

Trial information

Trial identification

Sponsor protocol code	114182
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01096056
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline Biologicals
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
Scientific contact	Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 February 2011
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 December 2010
Global end of trial reached?	Yes
Global end of trial date	13 December 2010
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the reactogenicity of seasonal trivalent influenza vaccine adjuvanted with various doses of the AS03 in terms of incidence of fever grade ≥ 2 (axillary temperature $>38^{\circ}\text{C}$) reported during 7 days follow-up period after any vaccination.

Protection of trial subjects:

As with all injectable vaccines, appropriate medical treatment was always readily available in case of anaphylactic reactions following the administration of the vaccine.

For this reason, the vaccinee remained under medical supervision for 30 minutes after vaccination.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 April 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Efficacy
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 40
Worldwide total number of subjects	40
EEA total number of subjects	40

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	40
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Influenza vaccine GSK2186877A formulation 1 Group
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Biological: Influenza vaccine GSK2186877A formulation 1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.

Investigational medicinal product name	Biological: Fluarix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.

Arm title	Influenza vaccine GSK2186877A formulation 2 Group
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	Biological: Influenza vaccine GSK2186877A formulation 2
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.

Investigational medicinal product name	Biological: Fluarix
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.

Number of subjects in period 1	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group
Started	20	20
Completed	20	19
Not completed	0	1
Lost to follow-up	-	1

Baseline characteristics

Reporting groups

Reporting group title	Influenza vaccine GSK2186877A formulation 1 Group
-----------------------	---

Reporting group description: -

Reporting group title	Influenza vaccine GSK2186877A formulation 2 Group
-----------------------	---

Reporting group description: -

Reporting group values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group	Total
Number of subjects	20	20	40
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	20	20	40
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: months			
arithmetic mean	23.2	18.6	
standard deviation	± 9.82	± 7.46	-
Gender categorical			
Units: Subjects			
Female	11	7	18
Male	9	13	22

End points

End points reporting groups

Reporting group title	Influenza vaccine GSK2186877A formulation 1 Group
Reporting group description: -	
Reporting group title	Influenza vaccine GSK2186877A formulation 2 Group
Reporting group description: -	

Primary: Number of subjects reporting fever grade 2 or higher

End point title	Number of subjects reporting fever grade 2 or higher ^[1]
End point description:	Fever grade greater than or equal to 2 i.e. ≥ 2 was defined as axillary temperature >38 degree centigrade ($^{\circ}\text{C}$).
End point type	Primary
End point timeframe:	Within 7 days following any vaccination with New generation influenza vaccine GSK2186877A

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Temperature [Units:subjects]	11	7		

Statistical analyses

No statistical analyses for this end point

Secondary: Haemagglutination Inhibition (HI) antibody titers

End point title	Haemagglutination Inhibition (HI) antibody titers
End point description:	Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included Flu A/CAL/7/09 H1N1, Flu A/Uru/716/07 H3N2 and FluB/Bri/60/08 Victoria antigens.
End point type	Secondary
End point timeframe:	At Day 0 and Day 42

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Units:Titers				
geometric mean (confidence interval 95%)				
Flu A/CAL/7/09 H1N1 strain at Day 0 (N=20;20)	13.7 (6.5 to 28.9)	35.4 (13.6 to 92.6)		
Flu A/CAL/7/09 H1N1 strain at Day 42 (N=20;19)	905.2 (649 to 1262.6)	617.1 (251 to 1516.8)		
Flu A/Uru/716/07 H3N2 strain at Day 0 (N=20;20)	14.9 (6.6 to 33.5)	7.6 (4.1 to 13.9)		
Flu A/Uru/716/07 H3N2 strain at Day 42 (N=20;19)	722.5 (473.8 to 1101.7)	160 (86.3 to 296.7)		
FluB/Bri/60/08 Victoria strain at Day 0 (N=20;20)	5.9 (4.1 to 8.5)	5.9 (4.1 to 8.5)		
FluB/Bri/60/08 Victoria strain at Day 42 (N=20;19)	460.5 (320.4 to 661.8)	63.1 (30.9 to 128.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: The number of subjects seropositive to HI antibodies

End point title	The number of subjects seropositive to HI antibodies
End point description: A seropositive subject was defined as a subject with antibody titer greater than or equal to 1:10. The vaccine strains included Flu A/CAL/7/09 H1N1, Flu A/Uru/716/07 H3N2 and FluB/Bri/60/08 Victoria antigens.	
End point type	Secondary
End point timeframe: At Day 0 and Day 42	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Flu A/CAL/7/09 H1N1 strain at Day 0 (N=20;20)	6	10		
Flu A/CAL/7/09 H1N1 strain at Day 42 (N=20;19)	20	19		
Flu A/Uru/716/07 H3N2 strain at Day 0 (N=20;20)	6	2		
Flu A/Uru/716/07 H3N2 strain at Day 42 (N=20;19)	20	19		

FluB/Bri/60/08 Victoria strain at Day 0 (N=20;20)	1	1		
FluB/Bri/60/08 Victoria strain at Day 42 (N=20;19)	20	19		

Statistical analyses

No statistical analyses for this end point

Secondary: The number of subjects seroprotected to HI antibodies

End point title	The number of subjects seroprotected to HI antibodies
End point description: A seroprotected subject was defined as a subject with a serum HI titre greater than or equal to 1:40 that usually is accepted as indicating protection. The vaccine strains included Flu A/CAL/7/09 H1N1, Flu A/Uru/716/07 H3N2 and FluB/Bri/60/08 Victoria antigens.	
End point type	Secondary
End point timeframe: At Day 0 and Day 42	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Flu A/CAL/7/09 H1N1 strain at Day 0 (N=20;20)	6	10		
Flu A/CAL/7/09 H1N1 strain at Day 42 (N=20;19)	20	19		
Flu A/Uru/716/07 H3N2 strain at Day 0 (N=20;20)	6	2		
Flu A/Uru/716/07 H3N2 strain at Day 42 (N=20;19)	20	19		
FluB/Bri/60/08 Victoria strain at Day 0 (N=20;20)	1	1		
FluB/Bri/60/08 Victoria strain at Day 42 (N=20;19)	20	14		

Statistical analyses

No statistical analyses for this end point

Secondary: The number of subjects seroconverted to HI antibodies

End point title	The number of subjects seroconverted to HI antibodies
End point description: A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and	

a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included Flu A/CAL/7/09 H1N1, Flu A/Uru/716/07 H3N2 and FluB/Bri/60/08 Victoria antigens.

End point type	Secondary
End point timeframe:	
Day 42	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	19		
Units: Subjects				
Flu A/CAL/7/09 H1N1 strain	20	19		
Flu A/Uru/716/07 H3N2 strain	20	19		
FluB/Bri/60/08 Victoria strain	20	14		

Statistical analyses

No statistical analyses for this end point

Secondary: HI antibody Geometric mean fold rise (GMFR)

End point title	HI antibody Geometric mean fold rise (GMFR)
End point description:	
GMFR was defined as the fold increase in serum HI GMTs post-vaccination compared to pre-vaccination. The vaccine strains included Flu A/CAL/7/09 H1N1, Flu A/Uru/716/07 H3N2 and FluB/Bri/60/08 Victoria antigens.	
End point type	Secondary
End point timeframe:	
Day 42	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	19		
Units: Units:fold increase				
geometric mean (confidence interval 95%)				
Flu A/CAL/7/09 H1N1 strain	66.3 (38.8 to 113.3)	19.6 (13.4 to 28.5)		
Flu A/Uru/716/07 H3N2 strain	48.5 (28 to 84.1)	20.7 (14.8 to 28.8)		

FluB/Bri/60/08 Victoria strain	77.4 (59.4 to 101)	10.5 (6.3 to 17.6)		
--------------------------------	--------------------	--------------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and grade 3 solicited local Adverse Events (AEs)

End point title	Number of subjects reporting any and grade 3 solicited local Adverse Events (AEs)
-----------------	---

End point description:

Grade 3 redness and swelling was > 50 millimeter (mm) and grade 3 pain was subjects crying when limb was moved/spontaneously painful. Any was occurrence of any local symptom regardless of their intensity grade.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 7 days following any vaccination with New generation influenza vaccine GSK2186877A

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Any pain	10	6		
Grade 3 pain	0	0		
Any redness	7	2		
Grade 3 redness	0	0		
Any swelling	6	1		
Grade 3 swelling	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of solicited local AEs

End point title	Duration of solicited local AEs
-----------------	---------------------------------

End point description:

Duration was defined as number of days with any grade of local symptoms following each dose of New generation influenza vaccine GSK2186877A. Dose 1 application of vaccine involved Influenza vaccine GSK2186877A formulation 1 Group and Influenza vaccine GSK2186877A formulation 2 Group while Dose 2 involved only Influenza vaccine GSK2186877A formulation 1 Group.

End point type	Secondary
End point timeframe:	
Within 7 days following any vaccination with New generation influenza vaccine GSK2186877A	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	6		
Units: Units:Days				
median (full range (min-max))				
Pain [Dose 1] (N=6;6)	1 (1 to 2)	1 (1 to 2)		
Pain [Dose 2] (N=7;0)	2 (1 to 2)	0 (0 to 0)		
Redness [Dose 1] (N=2;2)	3.5 (2 to 5)	1 (1 to 1)		
Redness [Dose 2] (N=6;0)	2.5 (2 to 3)	0 (0 to 0)		
Swelling [Dose 1] (N=1;1)	3 (3 to 3)	1 (1 to 1)		
Swelling [Dose 2] (N=5;0)	3 (2 to 4)	0 (0 to 0)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related solicited general AEs

End point title	Number of subjects reporting any, grade 3 and related solicited general AEs
End point description:	
Any temperature was defined as axillary temperature $\geq 37.5^{\circ}\text{C}$, grade 3 temperature was axillary temperature $> 39.0^{\circ}\text{C}$. For other symptoms, any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination. Grade 3 drowsiness was defined as general symptom that prevented normal activity, grade 3 irritability was crying that cannot be comforted/prevented normal activity, grade 3 loss of appetite was not eating at all and grade 3 vomiting was defined as ≥ 3 episode of vomiting/day. Related was symptom assessed by the investigator as causally related to vaccination.	
End point type	Secondary
End point timeframe:	
Within 7 days following any vaccination with New generation influenza vaccine GSK2186877A	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Any drowsiness	6	7		

Grade 3 drowsiness	0	1		
Related drowsiness	3	3		
Any irritability	7	9		
Grade 3 irritability	1	1		
Related irritability	4	4		
Any loss of appetite	12	5		
Grade 3 loss of appetite	0	1		
Related loss of appetite	5	3		
Any temperature	14	12		
Grade 3 temperature	2	1		
Related temperature	9	9		
Any vomiting	7	4		
Grade 3 vomiting	2	1		
Related vomiting	2	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of solicited general AEs

End point title	Duration of solicited general AEs
End point description:	
Duration was defined as number of days with any grade of local symptoms following each dose of New generation influenza vaccine GSK2186877A. Dose 1 application of vaccine involved subjects in Influenza vaccine GSK2186877A formulation 1 Group and Influenza vaccine GSK2186877A formulation 2 Group while Dose 2 application of vaccine involved only subjects in the Influenza vaccine GSK2186877A formulation 1 Group.	
End point type	Secondary
End point timeframe:	
Within 7 days following any vaccination with New generation influenza vaccine GSK2186877A	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	12		
Units: Units:Days				
median (full range (min-max))				
Drowsiness [Dose 1] (N=4;7)	1.5 (1 to 3)	2 (1 to 6)		
Drowsiness [Dose 2] (N=4;0)	2 (1 to 4)	0 (0 to 0)		
Irritability [Dose 1] (N=4;9)	2.5 (1 to 4)	2 (1 to 6)		
Irritability [Dose 2] (N=4;0)	1 (1 to 2)	0 (0 to 0)		
Loss of appetite [Dose 1] (N=9;5)	1 (1 to 3)	2 (1 to 4)		
Loss of appetite [Dose 2] (N=5;0)	5 (1 to 6)	0 (0 to 0)		
Temperature [Dose 1] (N=7;12)	1 (1 to 5)	1 (1 to 6)		
Temperature [Dose 2] (N=9;0)	1 (1 to 4)	0 (0 to 0)		
Vomiting [Dose 1] (N=5;4)	1 (1 to 1)	1 (1 to 2)		

Vomiting [Dose 2] (N=3;0)	1 (1 to 2)	0 (0 to 0)		
---------------------------	------------	------------	--	--

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related unsolicited AEs

End point title	Number of subjects reporting any, grade 3 and related unsolicited AEs
End point description: Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was event that prevented normal activities and Related was defined as unsolicited AE assessed by the investigator to be causally related to the study vaccination.	
End point type	Secondary
End point timeframe: Within 21 days after any vaccination with New generation influenza vaccine GSK2186877A	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Any AE(s)	14	12		
Grade 3 AE(s)	1	0		
Related AE(s)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any, grade 3 and related AEs with a medically attended visit (MAEs)

End point title	Number of subjects reporting any, grade 3 and related AEs with a medically attended visit (MAEs)
End point description: For each solicited and unsolicited AE the subject experienced, the subject was asked if they had received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination, grade 3 was defined as symptom that prevented normal activity and related was symptom assessed by the investigator as causally related to the study vaccination.	

End point type	Secondary
End point timeframe:	
Day 0 up to Month 7	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Any MAE(s)	18	20		
Grade 3 MAE(s)	3	3		
Related MAE(s)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any potential Immune-Mediated-Diseases (pIMDs)

End point title	Number of subjects reporting any potential Immune-Mediated-Diseases (pIMDs)
End point description:	
pIMDs are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology.	
End point type	Secondary
End point timeframe:	
Day 0 up to Month 7	

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Any pIMD [Units:Subjects]	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects reporting any and related serious adverse events (SAEs)

End point title	Number of subjects reporting any and related serious adverse events (SAEs)
-----------------	--

End point description:

SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was event assessed by the investigator as causally related to the study vaccination.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 up to Month 7

End point values	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	20	20		
Units: Subjects				
Any SAE (s)	0	3		
Related SAE(s)	0	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events were assessed from day 0 up to month 7. Systematically assessed frequent adverse events (AEs) and Non-systematically assessed frequent AEs were assessed during 7 day and 21 day post vaccination period.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	13.1

Reporting groups

Reporting group title	Influenza vaccine GSK2186877A formulation 1 Group
-----------------------	---

Reporting group description:

Subjects aged 6 to 35 months received 2 doses of new generation influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.

Reporting group title	Influenza vaccine GSK2186877A formulation 2 Group
-----------------------	---

Reporting group description:

Subjects aged 6 to 35 months received 1 dose of new generation influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.

Serious adverse events	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 20 (0.00%)	3 / 20 (15.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Nervous system disorders			
Syncope			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bronchopneumonia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Influenza vaccine GSK2186877A formulation 1 Group	Influenza vaccine GSK2186877A formulation 2 Group	
Total subjects affected by non-serious adverse events subjects affected / exposed	19 / 20 (95.00%)	18 / 20 (90.00%)	
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Pain			
alternative assessment type: Systematic			
subjects affected / exposed	10 / 20 (50.00%)	6 / 20 (30.00%)	
occurrences (all)	10	6	
Redness			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 20 (35.00%)	2 / 20 (10.00%)	
occurrences (all)	7	2	
Swelling			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 20 (30.00%)	1 / 20 (5.00%)	
occurrences (all)	6	1	
Drowsiness			
alternative assessment type: Systematic			
subjects affected / exposed	6 / 20 (30.00%)	7 / 20 (35.00%)	
occurrences (all)	6	7	
Irritability			
alternative assessment type: Systematic			
subjects affected / exposed	7 / 20 (35.00%)	9 / 20 (45.00%)	
occurrences (all)	7	9	
Loss of appetite			

<p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>12 / 20 (60.00%)</p> <p>12</p>	<p>5 / 20 (25.00%)</p> <p>5</p>	
<p>Temperature</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>14 / 20 (70.00%)</p> <p>14</p>	<p>12 / 20 (60.00%)</p> <p>12</p>	
<p>Vomiting</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 20 (35.00%)</p> <p>7</p>	<p>4 / 20 (20.00%)</p> <p>4</p>	
<p>Pyrexia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 20 (25.00%)</p> <p>5</p>	<p>0 / 20 (0.00%)</p> <p>0</p>	
<p>Eye disorders</p> <p>Conjunctivitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 20 (5.00%)</p> <p>1</p>	<p>0 / 20 (0.00%)</p> <p>0</p>	
<p>Gastrointestinal disorders</p> <p>Teething</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Toothache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting (unsolicited AE)</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 20 (5.00%)</p> <p>1</p> <p>0 / 20 (0.00%)</p> <p>0</p> <p>1 / 20 (5.00%)</p> <p>1</p>	<p>2 / 20 (10.00%)</p> <p>2</p> <p>1 / 20 (5.00%)</p> <p>1</p> <p>0 / 20 (0.00%)</p> <p>0</p>	
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Bronchial hyperreactivity</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hiccups</p>	<p>2 / 20 (10.00%)</p> <p>2</p> <p>1 / 20 (5.00%)</p> <p>1</p>	<p>2 / 20 (10.00%)</p> <p>2</p> <p>0 / 20 (0.00%)</p> <p>0</p>	

subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 20 (0.00%) 0	
Skin and subcutaneous tissue disorders			
Dermatitis diaper			
subjects affected / exposed	1 / 20 (5.00%)	2 / 20 (10.00%)	
occurrences (all)	1	2	
Rash			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	5 / 20 (25.00%)	7 / 20 (35.00%)	
occurrences (all)	5	7	
Otitis media acute			
subjects affected / exposed	3 / 20 (15.00%)	0 / 20 (0.00%)	
occurrences (all)	3	0	
Gastroenteritis			
subjects affected / exposed	1 / 20 (5.00%)	2 / 20 (10.00%)	
occurrences (all)	1	2	
Nasopharyngitis			
subjects affected / exposed	2 / 20 (10.00%)	0 / 20 (0.00%)	
occurrences (all)	2	0	
Bronchitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 20 (5.00%)	
occurrences (all)	0	1	
Cellulitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Otitis media			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Pharyngitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 20 (0.00%)	
occurrences (all)	1	0	
Tonsillitis			

subjects affected / exposed	1 / 20 (5.00%)	1 / 20 (5.00%)	
occurrences (all)	1	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 June 2010	<p>The reactogenicity data were collected in 20 subjects having received the first dose of GSK's seasonal influenza vaccine 7.5 µg HA per strain + AS03C and they suggest a trend towards an increase of fever after the first dose compared to the data that were collected during the first study phase in the 7.5 µg HA per strain + AS03D group.</p> <p>The observed incidence of any reported fever ($\geq 37.5^{\circ}$; axillary measurement) after the first dose is 60% in TIV-AS03C group compared to 35% in the TIV-AS03D group. Importantly, the incidence of grade 3 temperature (axillary temperature $\geq 39.1^{\circ}\text{C}$) was low (5.0%-one children among the 20 recruited), and the majority of fever episodes were short (1 day) and did not require medical attention. The follow-up for the participants already enrolled will be continued according to the protocol including assessment of all safety, reactogenicity and immunogenicity end-points. However according to the recommendations of the internal Vaccine Safety Monitoring Board, any further vaccination was suspended (i.e. the administration of the second dose of TIV-AS03C and the further enrolment in the group TIV-AS03B).</p> <p>Also the protocol was amended to proceed with an early analysis of the immunogenicity results of children who received 2 doses of the TIV-AS03D vaccine to evaluate the possible impact of high initial priming status which can contribute to the present findings and to evaluate how best to plan the further booster phase.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported